<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Obstructive sleep apnea and cardiovascular disease in adults
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Obstructive sleep apnea and cardiovascular disease in adults
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Obstructive sleep apnea and cardiovascular disease in adults
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Reena Mehra, MD, MS, FCCP, FAASM
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Nancy Collop, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Geraldine Finlay, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jun 05, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Obstructive sleep apnea (OSA) is a common sleep-related breathing disorder characterized by repetitive episodes of apnea or reduced inspiratory airflow due to upper airway obstruction during sleep. Patients with OSA are often obese and have an increased prevalence of numerous other cardiovascular risk factors, including hypertension and type 2 diabetes mellitus. Although OSA is two to four times more common in men, relationships of biomarkers of myocardial injury and incident heart failure in relation to OSA appear to be stronger in women than in men [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         Observational studies have demonstrated a consistent association between OSA and hypertension, coronary heart disease, cardiac arrhythmia, and heart failure. Although most studies have demonstrated these associations independent of the confounding influence of obesity, whether OSA lies directly along the causal pathway or is linked through common comorbidities such as obesity is not always clear in any given patient, and all of these diseases carry multifactorial etiologic risk. However, accumulating evidence also suggests that successful treatment of OSA with continuous positive airway pressure (CPAP) can improve cardiovascular outcomes.
        </p>
        <p>
         The association between OSA and cardiovascular disease and the potential impact of OSA-specific therapy on cardiovascular outcomes are discussed here. The evaluation and management of sleep-related breathing disorders in patients with heart failure and stroke are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7682.html" rel="external">
          "Sleep-disordered breathing in heart failure"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7716.html" rel="external">
          "Sleep-related breathing disorders and stroke"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H87370031">
         <span class="h1">
          PATHOPHYSIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with OSA experience repetitive episodes of apnea or reduced inspiratory airflow due to upper airway obstruction during sleep. These events are associated with intermittent hypoxemia and possibly hypercapnia and usually provoke an arousal from sleep. The arousal is associated with restoration of upper airway patency and ventilation.
        </p>
        <p>
         The resulting hemodynamic, autonomic, inflammatory, and metabolic effects of this abnormal breathing and arousal pattern may contribute to the pathogenesis of a range of cardiovascular diseases  (
         <a class="graphic graphic_figure graphicRef93834" href="/z/d/graphic/93834.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         OSA is associated with a significant increase in sympathetic activity during sleep, which in turn influences heart rate and blood pressure [
         <a href="#rid3">
          3
         </a>
         ]. Increased sympathetic activity appears to be induced through a variety of different mechanisms, including chemoreflex stimulation by hypoxia and hypercapnia, baroreflexes, pulmonary afferents, impairment in venous return to the heart, alterations in cardiac output, and possibly the arousal response. Endothelial dysfunction may also play a role [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3409642565">
         <span class="h1">
          CARDIOVASCULAR EVENTS
         </span>
        </p>
        <p class="headingAnchor" id="H84743934">
         <span class="h2">
          Clinical evidence
         </span>
         <span class="headingEndMark">
          —
         </span>
         Experimental and population-based data identify OSA as a significant risk factor for cardiovascular disease and support its association with increased cardiovascular morbidity and mortality [
         <a href="#rid5">
          5-9
         </a>
         ]. Observational data in men with severe OSA support the benefit of continuous positive airway pressure (CPAP) treatment on reduction of fatal and non-fatal cardiovascular events [
         <a href="#rid10">
          10
         </a>
         ]. Sex-specific differences have been observed such that with extended cohort follow-up, women had higher Troponin-T levels, greater left ventricular mass index and higher risk of heart failure and death compared with men [
         <a href="#rid1">
          1
         </a>
         ]. Therefore, several clinical trials have been designed to examine the effect of CPAP therapy on cardiovascular events [
         <a href="#rid11">
          11-15
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3237340402">
         <span class="h2">
          Impact of treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         While most studies report improvement in sleep-related respiratory events, daytime sleepiness, blood pressure control, and intermediate cardiovascular endpoints, none has unequivocally shown benefits in the reduction of cardiovascular events (eg, cardiovascular mortality, acute myocardial infarction, stroke) as a whole. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The Sleep Apnea Cardiovascular Endpoints (SAVE) study is one of the largest multicenter randomized clinical trials to examine the impact of CPAP on cardiovascular outcomes. In SAVE, 2717 patients with moderate to severe OSA and established cardiovascular disease were randomized to CPAP therapy plus usual care or usual care alone (eg, education, risk factor modification) and followed for 3.7 years (ie, secondary prevention) [
         <a href="#rid14">
          14
         </a>
         ]. Despite a reduction in the apnea-hypopnea index from 29 to 3.7 events per hour per night (ie, indicating overall adequate control of OSA), CPAP was not associated with a significant reduction in cardiovascular events (cardiovascular deaths, myocardial infarction, stroke or hospitalizations for heart failure, unstable angina or transient ischemic attack; 17 percent [CPAP] versus 15.4 percent [usual care]). Although the rate of cardiovascular events was slightly improved in those adherent to CPAP (ie, ≥4 hours per night), the benefit was not statistically significant. However, several aspects limited interpretability and generalizability including the exclusion of patients with "sleepy" OSA, patients at high risk of an accident and patients with severe hypoxemia, as well as use of automated oximetry data rather than polysomnography for diagnosis and an overall low adherence rate to CPAP (mean was 3.3 hours per night), which may have lessened the impact of the therapy on the outcome.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a similar population of non-sleepy OSA patients, smaller randomized trials reported a similar lack of benefit from CPAP during several years of follow-up in 725 patients with OSA who did not have established cardiovascular disease (ie, primary prevention), 224 patients who had just undergone coronary revascularization, and 140 patients with recent stroke [
         <a href="#rid11">
          11-13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Several meta-analyses of randomized trials of patients with OSA, have reported that compared with no treatment or sham, CPAP did not result in a reduction in the risk of major cardiovascular events (acute coronary events, stroke, or vascular death) or all-cause death [
         <a href="#rid15">
          15,16
         </a>
         ]. The lack of benefit was reported despite OSA severity as well as duration of therapy.
        </p>
        <p>
        </p>
        <p>
         Further randomized trials are required to fully elucidate whether or not clinically meaningful cardiovascular benefit can be derived from CPAP in patients with OSA. It also remains unclear whether the "sleepy" OSA patient may derive cardiovascular benefit from OSA treatment and whether considering larger sample sizes with longer duration follow-up may enhance the ability to detect significant cardiovascular benefit.
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          HYPERTENSION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypertension and OSA frequently coexist. OSA-related autonomic dysfunction is evidenced by elevated levels of plasma and urinary catecholamines and also peroneal microneurography [
         <a href="#rid17">
          17,18
         </a>
         ]. It has been well established that OSA is associated with lack of the normal pattern of reduction of blood pressure during sleep (ie, a nondipping blood pressure) [
         <a href="#rid18">
          18
         </a>
         ], even in those with established cardiovascular disease or risk on antihypertensive therapy [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1241319">
         <span class="h2">
          Clinical evidence
         </span>
         <span class="headingEndMark">
          —
         </span>
         Approximately 50 percent of patients with OSA have coexisting hypertension, which is often most elevated in the morning. Similarly, patients with resistant hypertension have a very high prevalence of OSA (see
         <a class="medical medical_review" href="/z/d/html/3818.html" rel="external">
          "Definition, risk factors, and evaluation of resistant hypertension", section on 'Obstructive sleep apnea'
         </a>
         ). Cross-sectional population-based studies consistently find an increased prevalence of hypertension in patients with OSA, compared with controls, which remains significant after controlling for potential confounding factors such as age and obesity [
         <a href="#rid5">
          5,20-24
         </a>
         ]. The association between hypertension and OSA has been noted across a variety of patient groups, including the general adult population, older adult patients [
         <a href="#rid25">
          25
         </a>
         ], those with spinal cord injury [
         <a href="#rid26">
          26
         </a>
         ], and stroke survivors [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
         Prospective longitudinal studies have also demonstrated an increased risk of incident hypertension in patients with OSA who are normotensive at baseline [
         <a href="#rid5">
          5,28
         </a>
         ], although this finding has not been entirely consistent [
         <a href="#rid29">
          29,30
         </a>
         ]. Most studies support a monotonic, dose-response effect between the severity of OSA and the likelihood of hypertension [
         <a href="#rid5">
          5,20-25
         </a>
         ]. As an example, a prospective epidemiologic cohort study of 709 subjects estimated that patients with mild OSA (apnea hypopnea index [AHI] of 5 to 15 events per hour of sleep) had twice the risk of newly identified incident systemic hypertension, compared with those with an AHI of 0 (adjusted odds ratio 2.03, 95% CI 1.29-3.17), while subjects with an AHI of ≥15 events per hour of sleep had nearly three times the risk (adjusted odds ratio 2.89, 95% CI 1.46-5.64)  (
         <a class="graphic graphic_figure graphicRef65555" href="/z/d/graphic/65555.html" rel="external">
          figure 2
         </a>
         ) [
         <a href="#rid5">
          5
         </a>
         ]. Another large study found that OSA was only modestly associated with incident systolic hypertension after adjusting for relevant confounders [
         <a href="#rid30">
          30
         </a>
         ]. However, those with a body mass index of &lt;27 kg/m
         <sup>
          2
         </sup>
         and a severe burden of apnea had an almost threefold higher odds of incident hypertension.
        </p>
        <p>
         Some studies have also found that OSA is not as strongly related to isolated systolic hypertension as it is to isolated diastolic or combined systolic/diastolic hypertension [
         <a href="#rid31">
          31
         </a>
         ]. Others have found that the severity of OSA during rapid eye movement (REM) sleep is more strongly associated with both prevalent and incident hypertension than OSA severity during non-REM sleep [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
         Observational data examining the natural history of the effect of continuous positive airway pressure therapy (CPAP) on incident hypertension suggest a benefit of OSA treatment. As an example, a prospective epidemiologic cohort study that followed 1889 individuals for a median of 12 years identified an increased risk of incident hypertension among those with OSA untreated with CPAP due to refusal (adjusted hazard ratio [HR] 2.0), nonadherence (HR 1.8), or ineligibility (HR 1.3), compared with controls; patients with OSA treated with CPAP had a lower risk of incident hypertension, compared with controls (HR 0.7) [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
         The association between OSA and hypertension appears to be particularly prominent in patients with resistant hypertension. In one study, OSA was found in 71 percent of patients with resistant hypertension, compared with 38 percent of patients with controlled systemic hypertension [
         <a href="#rid33">
          33
         </a>
         ]. In another study, severe compared with moderate OSA in those with increased cardiovascular risk was associated with increased blood pressure despite use of an intensive antihypertensive regimen [
         <a href="#rid34">
          34
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3818.html" rel="external">
          "Definition, risk factors, and evaluation of resistant hypertension", section on 'Obstructive sleep apnea'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Impact of treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Randomized trials and meta-analyses have found that effective treatment of OSA using positive airway pressure reduces systemic blood pressure, regardless of whether the patients are hypertensive at baseline [
         <a href="#rid35">
          35-46
         </a>
         ].
        </p>
        <p>
         Four key observations can be made on the basis of these trials:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         First, the reduction in systemic blood pressure due to positive airway pressure therapy is usually small, albeit clinically relevant. In a 2014 meta-analysis that included 30 randomized trials and over 1900 patients, CPAP therapy was associated with a mean net lowering in systolic blood pressure of 2.6 mmHg [
         <a href="#rid47">
          47
         </a>
         ]. The clinical relevance of this level of reduction is highlighted by data demonstrating that a 1 to 2 mmHg reduction in blood pressure is associated with a reduction in major cardiovascular events, stroke, and heart failure [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a large, randomized trial of 194 patients with resistant hypertension, those randomized to CPAP had a greater reduction in 24-hour mean blood pressure (3.1 mmHg) and 24-hour diastolic blood pressure (3.2 mmHg), but not 24-hour systolic blood pressure (3.1 mmHg, 95% CI -0.6-6.7), compared with those who did not receive CPAP [
         <a href="#rid49">
          49
         </a>
         ]. A meta-analysis using patient-level data from eight randomized trials also found that the presence of uncontrolled hypertension at baseline was an important predictor of reduction in blood pressure with CPAP therapy, independent of OSA severity [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Second, the reduction in systemic blood pressure due to positive airway pressure therapy appears to be less than that due to antihypertensive medication. In a randomized crossover trial of 23 patients with both untreated hypertension and untreated OSA, antihypertensive medication (
         <a class="drug drug_general" data-topicid="10036" href="/z/d/drug information/10036.html" rel="external">
          valsartan
         </a>
         160 mg per day) lowered mean 24-hour blood pressure significantly more than CPAP therapy (-9 versus -2.1 mmHg) [
         <a href="#rid51">
          51
         </a>
         ]. Moreover, for patients whose blood pressure was not controlled with CPAP or valsartan, an extended trial of treatment that combined the two therapies showed further significant reduction in blood pressure.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Third, although the finding that positive airway pressure therapy reduces systemic blood pressure has been fairly consistent, findings have not been universal [
         <a href="#rid52">
          52-56
         </a>
         ]. The conflicting results may be related to methodological differences among the trials, including different study populations, co-interventions, CPAP adherence rates, sample sizes, outcome measures (single time point or 24-hour blood pressure), and durations of follow-up. Some of the more common or important methodological differences include the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Use of antihypertensive medications – Studies have differed in terms of whether antihypertensive medications were allowed during the study and, if so, how they were initiated, maintained, or discontinued [
         <a href="#rid57">
          57
         </a>
         ]. Studies have also differed in terms of how antihypertensive therapy was accounted for in the analysis, which may contribute to the conflicting results.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Excessive daytime sleepiness – Most studies are comprised primarily of OSA patients with excessive daytime sleepiness. In those that have evaluated patients without excessive daytime sleepiness, most have found no reduction in the blood pressure or incidence of hypertension following the initiation of CPAP [
         <a href="#rid11">
          11,53,55,58
         </a>
         ]. One trial found only a small reduction in the diastolic blood pressure and may have been confounded by the inclusion of patients with OSA-related sleepiness that was not severe enough to be defined as excessive daytime sleepiness [
         <a href="#rid59">
          59
         </a>
         ]. Taken together, these trials suggest that blood pressure reduction achieved by CPAP therapy is less in non-sleepy patients than in sleepy patients [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         OSA severity – The decrease in blood pressure in response to treatment with CPAP has been shown to be related to the severity of sleep apnea (as measured by the degree of nocturnal hypoxemia), with a greater decrease in blood pressure among those with more severe OSA [
         <a href="#rid35">
          35
         </a>
         ]. The severity of hypoxemia varies among studies and may influence the results.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Follow-up duration – Most trials have performed follow-up assessments at two to three months. However, a randomized trial of 83 males with moderate to severe OSA, coronary heart disease, and verified hypertension showed a reduction in systolic blood pressure, but not diastolic blood pressure, compared with controls over a median follow-up period of 36 months [
         <a href="#rid60">
          60
         </a>
         ]. These results support a long-lasting benefit of systolic blood pressure reduction in patients with moderate to severe OSA treated with CPAP therapy. However, CPAP withdrawal may be associated with a rebound increase in blood pressure [
         <a href="#rid61">
          61
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fourth, alternative or CPAP-adjunctive approaches to improve blood pressure have also been studied. A multicenter randomized trial in 318 patients with moderate to severe OSA and increased cardiovascular risk demonstrated that CPAP was more effective than supplemental oxygen in reducing 24-hour mean arterial blood pressure (-2.8 mmHg, 95% CI -5.1 to -0.5) [
         <a href="#rid44">
          44
         </a>
         ]. These results suggest that pathways independent of hypoxia play a role in augmentation of blood pressure in OSA. In a per protocol analysis that included those with a prespecified CPAP adherence threshold, another randomized trial demonstrated a more pronounced reduction of mean arterial and systolic pressures with CPAP plus a weight loss intervention, compared with either approach alone [
         <a href="#rid62">
          62
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Among the therapies, the impact of positive airway pressure, the most common therapy used for sleep apnea, is the most widely studied [
         <a href="#rid35">
          35-40,42,46
         </a>
         ].
        </p>
        <p>
         In contrast, the effects of alternative therapies (eg, oral appliances or upper airway surgery) on blood pressure are less well studied but suggest similar benefit [
         <a href="#rid46">
          46,63,64
         </a>
         ]. One meta-analysis of 51 studies of patients with hypertension and obstructive sleep apnea reported that compared with patients on placebo or not receiving therapy, mandibular advancement devices were associated with a significant reduction in systolic blood pressure (SBP; -2.1 mmHg, 95% CI -0.8 to -3.4) and diastolic blood pressure (DBP; -1.9 mmHg; 95% CI -0.5 to -3.2) [
         <a href="#rid46">
          46
         </a>
         ]. In addition, the level SBP and DBP reduction was similar to that reported in patients treated with CPAP.
        </p>
        <p>
         Taken together, the evidence indicates that treatment of OSA with positive airway pressure reduces systemic blood pressure in many patients. However, the reduction is usually modest and may not occur in patients with longstanding systemic hypertension or without excessive sleepiness. Despite this small reduction, it should be noted that a decrease of only 2 mmHg in blood pressure is enough to significantly reduce cardiovascular risk. Such modest reductions may be attributable to limited ability to reverse vascular pathology in those with chronic exposure to OSA and underscore the notion that early and prolonged OSA treatment may be required as a more effective therapeutic preventative approach.
        </p>
        <p class="headingAnchor" id="H1243533">
         <span class="h1">
          CORONARY HEART DISEASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is increasing evidence that severe (but probably not mild) OSA is associated with an increased risk for cardiovascular events related to coronary heart disease, independent of obesity and other shared risk factors, and that comorbid OSA is a risk factor for worse outcomes in patients with established coronary heart disease. This effect may be mediated by the association between OSA and multiple vascular risk factors, including hypertension, decreased high density lipoproteins [
         <a href="#rid65">
          65
         </a>
         ], increased C-reactive protein [
         <a href="#rid66">
          66,67
         </a>
         ], increased homocysteine [
         <a href="#rid66">
          66
         </a>
         ], elevated blood glucose [
         <a href="#rid68">
          68,69
         </a>
         ], and insulin resistance/diabetes mellitus [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p>
         Concentrations of high-sensitivity troponin-I have been associated with increasing severity of OSA (defined by the apnea hypopnea index [AHI]) as well as nocturnal hypoxia (percentage sleep time &lt;90 percent oxygen saturation), suggesting that increasing OSA burden may result in low-grade myocardial injury [
         <a href="#rid70">
          70
         </a>
         ]. Subclinical markers of atherosclerosis such as coronary artery calcification, a predictor of major adverse cardiovascular events, have also been associated with increasing OSA severity.
        </p>
        <p class="headingAnchor" id="H1241780">
         <span class="h2">
          Clinical evidence
         </span>
         <span class="headingEndMark">
          —
         </span>
         The range of cardiovascular morbidity associated with OSA was demonstrated by a large, prospective, cohort study that followed 1651 men for a mean of 10 years following polysomnography [
         <a href="#rid10">
          10
         </a>
         ]. Patients with untreated, severe OSA (mean AHI of 43 events per hour of sleep) had a higher incidence of fatal and nonfatal cardiovascular events than untreated patients with mild-moderate OSA, simple snorers, and healthy participants, even after adjustment for confounding variables. Cardiovascular events included myocardial infarction, acute coronary syndrome, and stroke.
        </p>
        <p>
         These findings have been supported by numerous subsequent studies that also found an increased risk of cardiovascular events (including mortality) among patients with untreated, severe OSA, compared with patients without OSA [
         <a href="#rid6">
          6,7,71-73
         </a>
         ].It is important to keep in mind that such an association suggests but does not necessarily indicate a causal relationship.
        </p>
        <p>
         OSA may also exacerbate pre-existing coronary artery disease [
         <a href="#rid74">
          74
         </a>
         ]. In a prospective cohort study, polysomnography was performed on 89 consecutive patients who had undergone a percutaneous coronary intervention for acute coronary syndrome (53 with acute myocardial infarction and 36 with unstable angina) . OSA (defined as AHI ≥10 events per hour of sleep) was detected in 51 patients (57 percent). During a mean follow up of 227 days, the incidence of major adverse cardiac events (cardiac death, reinfarction, target vessel revascularization) was higher among patients with OSA than those without OSA (adjusted hazard ratio [HR] 11.6, 95% CI 2.2-62.2).
        </p>
        <p>
         While the evidence above supports the association between untreated, severe OSA and the development of adverse cardiovascular events (eg, myocardial infarction, acute coronary syndrome), the reverse may also be true; that is, myocardial infarction may be associated with worsening of sleep-disordered breathing. This was demonstrated by a prospective cohort study of 2721 individuals (mean age 62 years) without known cardiovascular disease who were followed for a mean of five years, which included polysomnography performed at baseline and at five years [
         <a href="#rid75">
          75
         </a>
         ]. Fifty-seven subjects (2 percent) had a myocardial infarction during the study. The adjusted AHI increased a mean of 6.37 respiratory events per hour of sleep among those who had a myocardial infarction, compared with only 2.71 respiratory events per hour of sleep among those who had not had a myocardial infarction. It was not determined whether the increased respiratory event rate among individuals who had a myocardial infarction only was due to an increase in obstructive events, central events, or both, although, among patients who developed either a myocardial infarction or heart failure, the rates of both obstructive and central respiratory events increased.
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Impact of treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Observational data suggest that treatment of OSA with positive airway pressure may reduce the incidence of cardiovascular events, including events related to coronary artery disease [
         <a href="#rid10">
          10,74,76,77
         </a>
         ]. Some of the larger studies supporting this effect include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A prospective cohort study followed 1651 men for a mean of 10 years following polysomnography [
         <a href="#rid10">
          10
         </a>
         ]. Patients with OSA who were treated with CPAP (mean AHI of 42 events per hour of sleep prior to therapy) had a lower incidence of fatal and nonfatal cardiovascular events than patients with untreated, severe OSA (mean AHI of 43 events per hour of sleep). In fact, the incidence of fatal and nonfatal cardiovascular events among patients treated with CPAP did not differ significantly from that in individuals without OSA. Cardiovascular events included myocardial infarction, acute coronary syndrome, and stroke.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A prospective cohort study followed 449 patients with mild or moderate OSA for a median of six years [
         <a href="#rid76">
          76
         </a>
         ]. Treatment of OSA (primarily CPAP) was associated with a reduction of the likelihood of a cardiovascular event (adjusted HR 0.36, 95% CI 0.21-0.62), compared with no treatment. Cardiovascular events were defined as myocardial infarction, stroke, or acute coronary syndrome requiring a revascularization procedure. An important limitation of this study was that combining patients with mild and moderate OSA made it impossible to determine whether treatment benefited only patients with moderate OSA, mild OSA, or both.
        </p>
        <p>
        </p>
        <p>
         A limitation of these studies is the nonrandomized design and the possibility that those who were not adherent with CPAP represent a group at increased cardiovascular risk due to engaging in unhealthy lifestyle behaviors or nonadherence with other aspects of their medical care.
        </p>
        <p>
         The potential benefit of OSA therapy on reducing cardiovascular events has not yet been confirmed in randomized trials. For the most part, randomized trials of positive airway pressure therapy in patients with OSA have been short-term studies that have not measured endpoints related to coronary heart disease. One exception was a multicenter randomized trial in which 725 patients without a history of cardiovascular events who had moderate to severe OSA (AHI ≥20 events per hour) and no daytime sleepiness (Epworth sleepiness scale [ESS] score ≤10) were randomly assigned to receive CPAP therapy or no active intervention [
         <a href="#rid11">
          11
         </a>
         ]. After a median follow-up of four years, there was no significant difference in the rate of systemic hypertension or cardiovascular events (including nonfatal myocardial infarction, nonfatal stroke, transient ischemic attack, hospitalization for unstable angina or arrhythmia, or cardiovascular death) in patients treated with CPAP, compared with controls (incidence density ratio 0.83, 95% CI 0.63-1.1). A post-hoc analysis suggested that CPAP therapy did reduce hypertension and cardiovascular events in those patients who adhered to CPAP for at least four hours per night.
        </p>
        <p class="headingAnchor" id="H1242522">
         <span class="h1">
          ATRIAL FIBRILLATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         A strong association (up to fourfold higher odds) between OSA and atrial fibrillation (AF), independent of obesity and other confounding influences, has been described in multiple studies, and limited observational data suggest that OSA may be a modifiable risk factor for recurrent AF after cardioversion or ablation.
        </p>
        <p>
         Several pathophysiologic features of OSA provide a basis of biologic plausibility for atrial arrhythmogenesis, including: autonomic dysfunction and hypoxia [
         <a href="#rid78">
          78
         </a>
         ], hypercapnia (particularly the recovery phase), and exaggerated negative intrathoracic pressures leading to increased juxtacardiac and transmural pressures affecting the thin-walled atria.
        </p>
        <p class="headingAnchor" id="H87368695">
         <span class="h2">
          Clinical evidence
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cross-sectional and case-control studies have found an increased prevalence of AF in patients with OSA, compared with controls or the general population [
         <a href="#rid79">
          79-81
         </a>
         ], although this finding has not been universal [
         <a href="#rid82">
          82
         </a>
         ]. In a study that included 400 patients with moderate to severe OSA, the prevalence of AF on 24-hour Holter monitoring was 3 percent, which was approximately threefold higher than the expected prevalence in the general population. In another large, cross-sectional study, there was an increased prevalence of AF in patients with and without sleep-disordered breathing by polysomnogram (5 versus 1 percent), which was independent of age, sex, body mass index, and prevalent cardiovascular disease including heart failure (odds ratio 4.0, 95% CI 1.0-15.7) [
         <a href="#rid79">
          79
         </a>
         ].
        </p>
        <p>
         Dose-response relationships have been observed in a cohort of nearly 3000 older men, with increasing severity of sleep-disordered breathing associated with increasing prevalence of AF [
         <a href="#rid83">
          83
         </a>
         ]. Such findings were more pronounced with central versus obstructive sleep apnea. Although not definitive, support for an immediate causal temporal relationship of respiratory events (mainly hypopneas) preceding paroxysms of AF has been demonstrated using a case crossover design [
         <a href="#rid84">
          84
         </a>
         ]. These findings suggest that discrete episodes of upper airway compromise may lead to proximate arrhythmia generation.
        </p>
        <p>
         Conversely, the prevalence of OSA in patients with AF is much higher, with estimates ranging from 30 to 80 percent [
         <a href="#rid80">
          80,85
         </a>
         ]. Most, but not all, studies have found that the association is independent of shared risks factors such as increased age, obesity, hypertension, and heart failure. (See
         <a class="medical medical_review" href="/z/d/html/1004.html" rel="external">
          "Epidemiology, risk factors, and prevention of atrial fibrillation", section on 'Obstructive sleep apnea'
         </a>
         .)
        </p>
        <p>
         Several studies have examined the relationship between OSA and the risk of incident AF. In a large clinic-based cohort, nocturnal hypoxia predicted a threefold increased risk of incident AF in those less than 65 years of age, even after adjustment for confounding by obesity [
         <a href="#rid86">
          86
         </a>
         ]. Another retrospective cohort study of nearly 7000 middle-aged adults demonstrated that those with an AHI &gt;5 had a 55 percent increased risk of incident AF over a median follow-up period of 12 years [
         <a href="#rid8">
          8
         </a>
         ]. Prospective data involving older men support an approximate twofold increase in odds of AF associated with baseline central sleep apnea or Cheyne-Stokes respirations over a 6.5-year mean follow-up period [
         <a href="#rid79">
          79
         </a>
         ].
        </p>
        <p>
         Accumulating data implicate OSA as a risk factor for recurrent AF after cardioversion or ablation. In a meta-analysis of six observational studies, a diagnosis of OSA increased the risk of recurrent AF after radiofrequency catheter ablation by 25 percent [
         <a href="#rid87">
          87
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H87368701">
         <span class="h2">
          Impact of treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Whether treatment of OSA improves AF burden and outcomes is unclear. Three meta-analyses have been conducted which identify that OSA is associated with greater risk of AF recurrence after catheter ablation, that CPAP confers a 42 percent reduction in AF recurrence, and that untreated OSA is associated with a 57 percent increased risk of AF recurrence [
         <a href="#rid88">
          88-91
         </a>
         ]. However, a small, randomized trial of non-sleepy patients with mild OSA (apnea hypopnea index [AHI] &gt;5) and AF following cardioversion identified no reduction in AF recurrence with CPAP [
         <a href="#rid92">
          92
         </a>
         ]. Another trial of minimally symptomatic patients with moderate to severe OSA (AHI &gt;15), also identified no difference in three-month AF burden with CPAP compared with supportive care [
         <a href="#rid93">
          93
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/949.html" rel="external">
          "Atrial fibrillation: Catheter ablation", section on 'Prevention of recurrence'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1243945">
         <span class="h1">
          OTHER ARRHYTHMIAS
         </span>
        </p>
        <p class="headingAnchor" id="H1207094">
         <span class="h2">
          Clinical evidence
         </span>
         <span class="headingEndMark">
          —
         </span>
         OSA is associated with nocturnal cardiac arrhythmias. The bradycardia-tachycardia phenomenon may be observed with respiratory events (apneas and hypopneas). During the apnea, there is absence of ventilation and hypoxic stimulation of the carotid body is vagotonic, resulting in bradycardia. Subsequent to the respiratory event, sympathetic activation occurs due to synergistic influences of hypoxia, hypercapnia, and increasing thoracoabdominal efforts resulting in tachycardia. Although it is unknown whether or not the relationship is causal, there may be a temporal relationship, with arrhythmias occurring more frequently after a respiratory event [
         <a href="#rid84">
          84
         </a>
         ]. Arrhythmogenesis is also enhanced in OSA due to intermittent hypoxia, which may result in delayed depolarization, respiratory acidosis resulting in triggered automaticity, and re-entrant mechanisms likely due to autonomic nervous system fluctuations.
        </p>
        <p>
         Although conduction delay arrhythmias including atrioventricular block and sinus pauses have been highlighted in older reports and anecdotally observed in OSA, multicenter epidemiologic data do not demonstrate a significant association of OSA and these arrhythmias compared with those with lesser degree or without OSA [
         <a href="#rid94">
          94
         </a>
         ]. As these bradyarrhythmias are likely more pronounced in severe OSA, older reports may reflect historical case finding selection bias during a time when primarily severe cases of OSA were detected and diagnosed. For example, bradyarrhythmias, including atrioventricular (AV) block, sinus pause, and asystole, occur in up to 18 percent of patients with severe OSA (ie, apnea hypopnea index [AHI] &gt;30 events per hour) and lower oxygen saturation nadirs during sleep [
         <a href="#rid95">
          95
         </a>
         ]. Bradyarrhythmias anecdotally appear to be more common during rapid eye movement (REM) sleep due to enhanced parasympathetic tone. In extreme cases, asystole can last longer than 10 seconds. The contribution of asystole to the increase in mortality associated with OSA is unclear. (See
         <a class="medical medical_review" href="/z/d/html/941.html" rel="external">
          "Permanent cardiac pacing: Overview of devices and indications"
         </a>
         .)
        </p>
        <p>
         Bradycardia and asystole in patients with OSA may result from enhanced vagal tone, structural disease of the conduction system, or both [
         <a href="#rid96">
          96
         </a>
         ]. In one study, 15 patients with OSA and asystole who underwent electrophysiology exams all had normal (or only slightly abnormal) sinus and AV node function [
         <a href="#rid97">
          97
         </a>
         ]. Activation of the parasympathetic nervous system may result from hypoventilation, hypoxemia, respiratory acidosis, or repeated intrathoracic pressure changes due to airway obstruction during sleep.
        </p>
        <p>
         Ventricular ectopy and tachyarrhythmias have also been associated with OSA [
         <a href="#rid98">
          98
         </a>
         ]. In an observational study, 228 patients with a sleep-related breathing disorder (respiratory disturbance index [RDI] ≥30 events per hour of sleep) were compared with 338 control subjects (RDI &lt;5 events per hour of sleep) [
         <a href="#rid79">
          79
         </a>
         ]. The sleep-related breathing disorder group had a higher prevalence of nocturnal atrial fibrillation (AF; 4.8 versus 0.9 percent), nonsustained ventricular tachycardia (5.3 versus 1.2 percent), and complex ventricular ectopy (25 versus 14.5 percent). These relationships persisted after adjustment for confounding variables. Examples of complex ventricular ectopy include nonsustained ventricular tachycardia, bigeminy, trigeminy, and quadrigeminy. In a large cohort of older men, severity of obstructive versus central sleep apnea appeared to be more closely related to ventricular arrhythmias than atrial fibrillation, as did the extent of hypoxia [
         <a href="#rid83">
          83
         </a>
         ].
        </p>
        <p>
         In a cohort study of more than 10,000 patients that identified nadir oxygen saturation as a predictor of sudden cardiac death (SCD), it is noteworthy that 31 percent of those with SCD had definite ventricular arrhythmia as a verified cause, and ventricular ectopy or nonsustained ventricular tachycardia was an independent risk factor for SCD among those with OSA (hazard ratio [HR] 4.1, 95% CI 1.6-10.1) [
         <a href="#rid99">
          99
         </a>
         ].
        </p>
        <p>
         The biologic plausibility of the relationship of OSA with clinically significant cardiac arrhythmias is supported by data demonstrating that OSA is associated with QT prolongation corrected for heart rate in patients with congenital long QT syndrome (LQTS), a familial arrhythmogenic cardiac channelopathy associated with prolonged ventricular repolarization [
         <a href="#rid100">
          100
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1207100">
         <span class="h2">
          Impact of treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Preliminary data support a role for positive airway pressure therapy in abolishing nocturnal ventricular asystole and improving other arrhythmias in patients with OSA [
         <a href="#rid97">
          97,101,102
         </a>
         ].
        </p>
        <p>
         In a prospective cohort study, a loop recorder capable of monitoring the heart rhythm for 16 months was implanted in 23 patients with moderate or severe OSA [
         <a href="#rid101">
          101
         </a>
         ]. Recording was performed for two months prior to the initiation of continuous positive airway pressure (CPAP) and then for 14 months after initiation of CPAP. Nocturnal ventricular bradycardia or asystole were noted in 47 percent of patients prior to the initiation of CPAP. This decreased by eight weeks. No nocturnal arrhythmias were detected during the final six months. A randomized trial in patients with heart failure and OSA demonstrated a 58 percent reduction in the frequency of ventricular premature beats in patients treated with CPAP, while there was no significant reduction in the control arm [
         <a href="#rid103">
          103
         </a>
         ].
        </p>
        <p>
         There are several important gaps in our knowledge about the impact of OSA therapy on nocturnal arrhythmias:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         It is unknown whether nocturnal arrhythmia suppression improves mortality.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diurnal patterns of arrhythmia burden in relation to OSA require further study.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         There are few data about the impact of therapy on arrhythmias other than ventricular bradycardia or asystole.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The effect of therapies other than positive airway pressure (eg, oral appliances, pharmacotherapy, surgery, tracheostomy) on nocturnal arrhythmias is unknown.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H87369134">
         <span class="h1">
          SUDDEN CARDIAC DEATH
         </span>
         <span class="headingEndMark">
          —
         </span>
         Limited data suggest that severe or untreated OSA may increase risk of fatal cardiac arrhythmias [
         <a href="#rid77">
          77,99,104
         </a>
         ].
        </p>
        <p>
         A longitudinal study of 107 patients with OSA followed for seven years found that the rate of sudden cardiac death (SCD) was increased in patients who had discontinued positive airway pressure therapy, compared with those who were adherent (7 versus 0 percent) [
         <a href="#rid77">
          77
         </a>
         ]. In the absence of OSA or other sleep disorders, sleep is considered to be cardioprotective, typically associated with a nadir of cardiovascular risk. However, those with OSA appear to have a nocturnal (midnight to 6 AM) predilection to SCD, with an approximately threefold increased risk, compared with the general population and those without OSA [
         <a href="#rid104">
          104
         </a>
         ].
        </p>
        <p>
         In a large, observational study of over 10,000 individuals referred for diagnostic polysomnography, nearly 80 percent of whom met criteria for OSA, several indicators of OSA severity (nadir nocturnal oxygen saturation, apnea hypopnea index [AHI] of 20 or greater) were associated with increased risk of incident SCD (fatal or resuscitated), although at a much lower magnitude of risk than established factors such as coronary heart disease, cardiomyopathy, and heart failure [
         <a href="#rid99">
          99
         </a>
         ]. Nadir SpO2 was the only independent sleep-disordered breathing predictor of SCD in the multivariate model. (See
         <a class="medical medical_review" href="/z/d/html/963.html" rel="external">
          "Overview of sudden cardiac arrest and sudden cardiac death"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H27159755">
         <span class="h1">
          HEART FAILURE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sleep-disordered breathing, which includes both OSA and central sleep apnea, is commonly observed in patients with heart failure, with a prevalence of 50 to 75 percent in those with reduced ejection fraction. OSA may be underdiagnosed in this population since typical symptoms of heart failure, such as nocturnal dyspnea and nocturia related to diuretics, may be ascribed to heart failure when they actually represent signs and symptoms of OSA. The pathophysiology of sleep-disordered breathing and heart failure involves a variety of mechanisms including obstructive apneas which increase left ventricular transmural pressures in response to increasingly negative intrathoracic pressure. This results in reduction of left ventricular preload and increased afterload [
         <a href="#rid105">
          105
         </a>
         ]. Neurohumoral effects involve pulmonary congestion which stimulates pulmonary vagal irritant receptors resulting in hyperventilation and elicitation of central apnea [
         <a href="#rid105">
          105
         </a>
         ]. Rostral neck edema is an important factor in both obstructive and central apnea generation in heart failure [
         <a href="#rid106">
          106
         </a>
         ]. Sleep-disordered breathing is important to recognize since its presence is a negative prognostic factor, and treatment can improve heart failure-related outcomes such as left ventricular ejection fraction, walk distance, and catecholamine levels [
         <a href="#rid107">
          107
         </a>
         ]. Although treatment with continuous positive airway pressure (CPAP) may be beneficial in those with central sleep apnea (CSA) [
         <a href="#rid108">
          108
         </a>
         ], those with systolic heart failure (ejection fraction ≤45 percent) and OSA treated with adaptive servo-ventilation (ASV) versus standard medical management have increased all-cause and cardiovascular-specific mortality, such that ASV is avoided in this population [
         <a href="#rid109">
          109,110
         </a>
         ]. This is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7682.html" rel="external">
          "Sleep-disordered breathing in heart failure"
         </a>
         .)
        </p>
        <p>
         OSA may itself be a risk factor for incident heart failure and for recurrence of heart failure after an episode of acute cardiogenic pulmonary edema [
         <a href="#rid7">
          7,73,111,112
         </a>
         ]. This was suggested by a prospective cohort study of 1927 men and 2495 women without baseline heart failure who were followed for a median of 8.7 years after baseline polysomnography [
         <a href="#rid7">
          7
         </a>
         ]. Among men, OSA appeared to be associated with an increased risk of developing heart failure, even after adjustment for potential confounders. The increased risk appeared to be highest among men with severe OSA (defined as an apnea hypopnea index [AHI] &gt;30 events per hour of sleep), who were 58 percent more likely to develop heart failure than those with an AHI &lt;5. OSA was not associated with heart failure among women; however, there may have been an insufficient sample size to detect a significant association. Cohort studies performed since then have shown similar results [
         <a href="#rid73">
          73
         </a>
         ]. CSA and Cheyne-Stokes respirations also increase risk of incident heart failure by approximately 80 percent and twofold respectively in a community-based study of older men [
         <a href="#rid113">
          113
         </a>
         ]. One study of a nationwide database suggested that CPAP may lower the risk of heart failure [
         <a href="#rid112">
          112
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1243649">
         <span class="h1">
          PULMONARY HYPERTENSION
         </span>
        </p>
        <p class="headingAnchor" id="H1243655">
         <span class="h2">
          Clinical evidence
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prevalence of pulmonary hypertension in patients with moderate to severe OSA is approximately 20 percent [
         <a href="#rid114">
          114,115
         </a>
         ]. When present in patients without coexisting lung disease, the degree of pulmonary hypertension is typically mild. Risk factors for pulmonary hypertension identified in one or more studies include comorbid lung disease, daytime hypoxemia, increasing apnea hypopnea index (AHI), and comorbid obesity hypoventilation syndrome. (See
         <a class="medical medical_review" href="/z/d/html/7698.html" rel="external">
          "Clinical manifestations and diagnosis of obesity hypoventilation syndrome"
         </a>
         .)
        </p>
        <p>
         The presence of pulmonary hypertension may have prognostic importance in patients with OSA. An observational study of 83 patients with OSA (defined as clinical suspicion plus an AHI &gt;5 events/hour) who underwent pulmonary artery catheterization for unspecified reasons found that one-, four-, and eight-year survival rates were lower among patients with pulmonary hypertension (93, 75, and 43 percent, respectively) than among those without pulmonary hypertension (100, 90, and 76 percent, respectively) [
         <a href="#rid116">
          116
         </a>
         ]. The study defined pulmonary hypertension as a mean pulmonary arterial pressure &gt;25 mmHg at rest. OSA-PH has also been associated with decreased functional capacity and quality of life [
         <a href="#rid117">
          117,118
         </a>
         ]. Data support that nocturnal hypoxia, more so than sleep apnea defined by the apnea hypopnea index, is associated with increased mortality in PH [
         <a href="#rid119">
          119
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1243661">
         <span class="h2">
          Impact of treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nasal CPAP, in several studies, has been shown to reduce pulmonary arterial systolic pressure (sPAP) and pulmonary vascular resistance (PVR) in patients with obstructive sleep apnea (OSA) over a period of three to four months [
         <a href="#rid120">
          120,121
         </a>
         ]. In one trial, 23 patients with OSA were randomly assigned to receive therapeutic or subtherapeutic continuous positive airway pressure (CPAP) for 12 weeks [
         <a href="#rid121">
          121
         </a>
         ]. Therapeutic CPAP reduced the estimated pulmonary artery systolic pressure from 29 to 24 mmHg. The extent of reduction was greatest among patients who had OSA plus pulmonary hypertension.
        </p>
        <p>
         Surgical weight loss in OSA may also result in improved pulmonary hemodynamics . The impact of other therapies (eg, oral appliances, pharmacotherapy, surgery, tracheostomy) on pulmonary hypertension is unknown.
        </p>
        <p>
         While treatment targeting OSA with positive airway pressure reduces pulmonary arterial systolic pressure in many patients, the reduction is modest, and evidence of improved patient-important outcomes (eg, mortality) is lacking. Therapy directed at the pulmonary hypertension is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/8250.html" rel="external">
          "Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2787571">
         <span class="h1">
          VENOUS THROMBOEMBOLISM
         </span>
         <span class="headingEndMark">
          —
         </span>
         OSA may be a risk factor for venous thromboembolism (VTE). One review of 15 studies reported that OSA may be an independent risk factor for VTE and that the risk may be two- to threefold higher than in those without OSA [
         <a href="#rid122">
          122
         </a>
         ]. The impact of treatment with positive airway pressure is unknown. This is consistent with observation of increased hypercoagulable markers including fibrinogen and plasminogen activator inhibitor-1, which appear to demonstrate diurnal patterning with increases in the morning (after OSA-related overnight physiologic stress) relative to the evening even in those with a milder degree of OSA [
         <a href="#rid94">
          94
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H706841140">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/113310.html" rel="external">
          "Society guideline links: Sleep-related breathing disorders in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition
         </strong>
         - Obstructive sleep apnea (OSA) is a disorder characterized by repetitive episodes of apnea or reduced inspiratory airflow due to upper airway obstruction during sleep, despite an increase in respiratory effort. The resulting hemodynamic, autonomic, inflammatory, and metabolic effects of this abnormal breathing and arousal pattern may contribute to the pathogenesis of a range of cardiovascular diseases. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Impact of OSA therapy on cardiovascular events overall
         </strong>
         - Although OSA is a risk factor for cardiovascular disease, there is no convincing evidence that treatment of OSA with CPAP is associated with a reduction on cardiovascular events as a whole (cardiovascular mortality, myocardial infarction, stroke). (See
         <a class="local">
          'Cardiovascular events'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hypertension - Hypertension and OSA frequently coexist. Evidence that OSA may be a cause of hypertension includes the increased prevalence and incidence of hypertension among patients
         </strong>
         with OSA, an observed dose-response effect between the severity of OSA and the likelihood of hypertension, and the fact that treatment of OSA can lower blood pressure, albeit modestly, but by levels that are clinically significant. (See
         <a class="local">
          'Hypertension'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Coronary artery disease
         </strong>
         - There is increasing evidence that severe (but probably not mild) OSA is associated with an increased risk for cardiovascular events related to coronary heart disease, independent of obesity and other shared risk factors, and that comorbid OSA is a risk factor for worse outcomes in patients with established coronary heart disease. It is not yet clear whether treatment of OSA with positive airway pressure therapy or other modalities can improve outcomes related to coronary heart disease. (See
         <a class="local">
          'Coronary heart disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Atrial fibrillation
         </strong>
         - Patients with OSA have an increased prevalence of atrial fibrillation (AF), compared with the general population and control subjects, and patients with established AF have a high prevalence of comorbid OSA. Limited observational data suggest that OSA may be a modifiable risk factor for recurrent AF after cardioversion or ablation. (See
         <a class="local">
          'Atrial fibrillation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other arrythmias
         </strong>
         - OSA has been associated with prolongation of the QT interval in those predisposed to prolonged ventricular repolarization, the latter providing a potential mechanism for the observed sudden nocturnal cardiac death observed in OSA. (See
         <a class="local">
          'Other arrhythmias'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Heart failure
         </strong>
         - Sleep-disordered breathing is common in patients with heart failure, and OSA and possibly central sleep apnea (CSA) may be risk factors for incident heart failure in men. Bidirectional relationships are likely at play in terms of these sleep-disordered breathing subtypes and heart failure. (See
         <a class="local">
          'Heart failure'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pulmonary hypertension
         </strong>
         - Pulmonary hypertension is present in approximately 20 percent of patients with moderate to severe OSA and may be associated with decreased survival. (See
         <a class="local">
          'Pulmonary hypertension'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H389964292">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Renaud Tamisier, MD, and J Woodrow Weiss, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Roca GQ, Redline S, Claggett B, et al. Sex-Specific Association of Sleep Apnea Severity With Subclinical Myocardial Injury, Ventricular Hypertrophy, and Heart Failure Risk in a Community-Dwelling Cohort: The Atherosclerosis Risk in Communities-Sleep Heart Health Study. Circulation 2015; 132:1329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bradley TD, Floras JS. Obstructive sleep apnoea and its cardiovascular consequences. Lancet 2009; 373:82.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friedman O, Logan AG. The price of obstructive sleep apnea-hypopnea: hypertension and other ill effects. Am J Hypertens 2009; 22:474.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seif F, Patel SR, Walia H, et al. Association between obstructive sleep apnea severity and endothelial dysfunction in an increased background of cardiovascular burden. J Sleep Res 2013; 22:443.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000; 342:1378.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Punjabi NM, Caffo BS, Goodwin JL, et al. Sleep-disordered breathing and mortality: a prospective cohort study. PLoS Med 2009; 6:e1000132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gottlieb DJ, Yenokyan G, Newman AB, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. Circulation 2010; 122:352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cadby G, McArdle N, Briffa T, et al. Severity of OSA is an independent predictor of incident atrial fibrillation hospitalization in a large sleep-clinic cohort. Chest 2015; 148:945.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Redline S, Yenokyan G, Gottlieb DJ, et al. Obstructive sleep apnea-hypopnea and incident stroke: the sleep heart health study. Am J Respir Crit Care Med 2010; 182:269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005; 365:1046.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barbé F, Durán-Cantolla J, Sánchez-de-la-Torre M, et al. Effect of continuous positive airway pressure on the incidence of hypertension and cardiovascular events in nonsleepy patients with obstructive sleep apnea: a randomized controlled trial. JAMA 2012; 307:2161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peker Y, Glantz H, Eulenburg C, et al. Effect of Positive Airway Pressure on Cardiovascular Outcomes in Coronary Artery Disease Patients with Nonsleepy Obstructive Sleep Apnea. The RICCADSA Randomized Controlled Trial. Am J Respir Crit Care Med 2016; 194:613.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parra O, Sánchez-Armengol A, Bonnin M, et al. Early treatment of obstructive apnoea and stroke outcome: a randomised controlled trial. Eur Respir J 2011; 37:1128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McEvoy RD, Antic NA, Heeley E, et al. CPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea. N Engl J Med 2016; 375:919.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yu J, Zhou Z, McEvoy RD, et al. Association of Positive Airway Pressure With Cardiovascular Events and Death in Adults With Sleep Apnea: A Systematic Review and Meta-analysis. JAMA 2017; 318:156.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           da Silva Paulitsch F, Zhang L. Continuous positive airway pressure for adults with obstructive sleep apnea and cardiovascular disease: a meta-analysis of randomized trials. Sleep Med 2019; 54:28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elmasry A, Lindberg E, Hedner J, et al. Obstructive sleep apnoea and urine catecholamines in hypertensive males: a population-based study. Eur Respir J 2002; 19:511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Narkiewicz K, Kato M, Phillips BG, et al. Nocturnal continuous positive airway pressure decreases daytime sympathetic traffic in obstructive sleep apnea. Circulation 1999; 100:2332.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seif F, Patel SR, Walia HK, et al. Obstructive sleep apnea and diurnal nondipping hemodynamic indices in patients at increased cardiovascular risk. J Hypertens 2014; 32:267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lavie P, Herer P, Hoffstein V. Obstructive sleep apnoea syndrome as a risk factor for hypertension: population study. BMJ 2000; 320:479.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nieto FJ, Young TB, Lind BK, et al. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA 2000; 283:1829.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Young T, Peppard P, Palta M, et al. Population-based study of sleep-disordered breathing as a risk factor for hypertension. Arch Intern Med 1997; 157:1746.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grote L, Ploch T, Heitmann J, et al. Sleep-related breathing disorder is an independent risk factor for systemic hypertension. Am J Respir Crit Care Med 1999; 160:1875.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bixler EO, Vgontzas AN, Lin HM, et al. Association of hypertension and sleep-disordered breathing. Arch Intern Med 2000; 160:2289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roche F, Pépin JL, Achour-Crawford E, et al. At 68 years, unrecognised sleep apnoea is associated with elevated ambulatory blood pressure. Eur Respir J 2012; 40:649.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LaVela SL, Burns SP, Goldstein B, et al. Dysfunctional sleep in persons with spinal cord injuries and disorders. Spinal Cord 2012; 50:682.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cereda CW, Tamisier R, Manconi M, et al. Endothelial dysfunction and arterial stiffness in ischemic stroke: the role of sleep-disordered breathing. Stroke 2013; 44:1175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marin JM, Agusti A, Villar I, et al. Association between treated and untreated obstructive sleep apnea and risk of hypertension. JAMA 2012; 307:2169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Connor GT, Caffo B, Newman AB, et al. Prospective study of sleep-disordered breathing and hypertension: the Sleep Heart Health Study. Am J Respir Crit Care Med 2009; 179:1159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cano-Pumarega I, Durán-Cantolla J, Aizpuru F, et al. Obstructive sleep apnea and systemic hypertension: longitudinal study in the general population: the Vitoria Sleep Cohort. Am J Respir Crit Care Med 2011; 184:1299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haas DC, Foster GL, Nieto FJ, et al. Age-dependent associations between sleep-disordered breathing and hypertension: importance of discriminating between systolic/diastolic hypertension and isolated systolic hypertension in the Sleep Heart Health Study. Circulation 2005; 111:614.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mokhlesi B, Finn LA, Hagen EW, et al. Obstructive sleep apnea during REM sleep and hypertension. results of the Wisconsin Sleep Cohort. Am J Respir Crit Care Med 2014; 190:1158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gonçalves SC, Martinez D, Gus M, et al. Obstructive sleep apnea and resistant hypertension: a case-control study. Chest 2007; 132:1858.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walia HK, Li H, Rueschman M, et al. Association of severe obstructive sleep apnea and elevated blood pressure despite antihypertensive medication use. J Clin Sleep Med 2014; 10:835.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pepperell JC, Ramdassingh-Dow S, Crosthwaite N, et al. Ambulatory blood pressure after therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised parallel trial. Lancet 2002; 359:204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Faccenda JF, Mackay TW, Boon NA, Douglas NJ. Randomized placebo-controlled trial of continuous positive airway pressure on blood pressure in the sleep apnea-hypopnea syndrome. Am J Respir Crit Care Med 2001; 163:344.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Becker HF, Jerrentrup A, Ploch T, et al. Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea. Circulation 2003; 107:68.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dimsdale JE, Loredo JS, Profant J. Effect of continuous positive airway pressure on blood pressure : a placebo trial. Hypertension 2000; 35:144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haentjens P, Van Meerhaeghe A, Moscariello A, et al. The impact of continuous positive airway pressure on blood pressure in patients with obstructive sleep apnea syndrome: evidence from a meta-analysis of placebo-controlled randomized trials. Arch Intern Med 2007; 167:757.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bazzano LA, Khan Z, Reynolds K, He J. Effect of nocturnal nasal continuous positive airway pressure on blood pressure in obstructive sleep apnea. Hypertension 2007; 50:417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sharma SK, Agrawal S, Damodaran D, et al. CPAP for the metabolic syndrome in patients with obstructive sleep apnea. N Engl J Med 2011; 365:2277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alajmi M, Mulgrew AT, Fox J, et al. Impact of continuous positive airway pressure therapy on blood pressure in patients with obstructive sleep apnea hypopnea: a meta-analysis of randomized controlled trials. Lung 2007; 185:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Montesi SB, Edwards BA, Malhotra A, Bakker JP. The effect of continuous positive airway pressure treatment on blood pressure: a systematic review and meta-analysis of randomized controlled trials. J Clin Sleep Med 2012; 8:587.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gottlieb DJ, Punjabi NM, Mehra R, et al. CPAP versus oxygen in obstructive sleep apnea. N Engl J Med 2014; 370:2276.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tamisier R, Tan CO, Pepin JL, et al. Blood Pressure Increases in OSA due to Maintained Neurovascular Sympathetic Transduction: Impact of CPAP. Sleep 2015; 38:1973.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bratton DJ, Gaisl T, Wons AM, Kohler M. CPAP vs Mandibular Advancement Devices and Blood Pressure in Patients With Obstructive Sleep Apnea: A Systematic Review and Meta-analysis. JAMA 2015; 314:2280.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fava C, Dorigoni S, Dalle Vedove F, et al. Effect of CPAP on blood pressure in patients with OSA/hypopnea a systematic review and meta-analysis. Chest 2014; 145:762.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turnbull F, Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362:1527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martínez-García MA, Capote F, Campos-Rodríguez F, et al. Effect of CPAP on blood pressure in patients with obstructive sleep apnea and resistant hypertension: the HIPARCO randomized clinical trial. JAMA 2013; 310:2407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bakker JP, Edwards BA, Gautam SP, et al. Blood pressure improvement with continuous positive airway pressure is independent of obstructive sleep apnea severity. J Clin Sleep Med 2014; 10:365.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pépin JL, Tamisier R, Barone-Rochette G, et al. Comparison of continuous positive airway pressure and valsartan in hypertensive patients with sleep apnea. Am J Respir Crit Care Med 2010; 182:954.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Campos-Rodriguez F, Grilo-Reina A, Perez-Ronchel J, et al. Effect of continuous positive airway pressure on ambulatory BP in patients with sleep apnea and hypertension: a placebo-controlled trial. Chest 2006; 129:1459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robinson GV, Smith DM, Langford BA, et al. Continuous positive airway pressure does not reduce blood pressure in nonsleepy hypertensive OSA patients. Eur Respir J 2006; 27:1229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mansfield DR, Gollogly NC, Kaye DM, et al. Controlled trial of continuous positive airway pressure in obstructive sleep apnea and heart failure. Am J Respir Crit Care Med 2004; 169:361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barbé F, Mayoralas LR, Duran J, et al. Treatment with continuous positive airway pressure is not effective in patients with sleep apnea but no daytime sleepiness. a randomized, controlled trial. Ann Intern Med 2001; 134:1015.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muxfeldt ES, Margallo V, Costa LM, et al. Effects of continuous positive airway pressure treatment on clinic and ambulatory blood pressures in patients with obstructive sleep apnea and resistant hypertension: a randomized controlled trial. Hypertension 2015; 65:736.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parati G, Lombardi C. Control of hypertension in nonsleepy patients with obstructive sleep apnea. Am J Respir Crit Care Med 2010; 181:650.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Craig SE, Kohler M, Nicoll D, et al. Continuous positive airway pressure improves sleepiness but not calculated vascular risk in patients with minimally symptomatic obstructive sleep apnoea: the MOSAIC randomised controlled trial. Thorax 2012; 67:1090.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barbé F, Durán-Cantolla J, Capote F, et al. Long-term effect of continuous positive airway pressure in hypertensive patients with sleep apnea. Am J Respir Crit Care Med 2010; 181:718.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang Z, Liu Z, Luo Q, et al. Long-term effects of continuous positive airway pressure on blood pressure and prognosis in hypertensive patients with coronary heart disease and obstructive sleep apnea: a randomized controlled trial. Am J Hypertens 2015; 28:300.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwarz EI, Schlatzer C, Rossi VA, et al. Effect of CPAP Withdrawal on BP in OSA: Data from Three Randomized Controlled Trials. Chest 2016; 150:1202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chirinos JA, Gurubhagavatula I, Teff K, et al. CPAP, weight loss, or both for obstructive sleep apnea. N Engl J Med 2014; 370:2265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iftikhar IH, Hays ER, Iverson MA, et al. Effect of oral appliances on blood pressure in obstructive sleep apnea: a systematic review and meta-analysis. J Clin Sleep Med 2013; 9:165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andrén A, Hedberg P, Walker-Engström ML, et al. Effects of treatment with oral appliance on 24-h blood pressure in patients with obstructive sleep apnea and hypertension: a randomized clinical trial. Sleep Breath 2013; 17:705.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Börgel J, Sanner BM, Bittlinsky A, et al. Obstructive sleep apnoea and its therapy influence high-density lipoprotein cholesterol serum levels. Eur Respir J 2006; 27:121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Can M, Açikgöz S, Mungan G, et al. Serum cardiovascular risk factors in obstructive sleep apnea. Chest 2006; 129:233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zouaoui Boudjeltia K, Van Meerhaeghe A, Doumit S, et al. Sleep apnoea-hypopnoea index is an independent predictor of high-sensitivity C-reactive protein elevation. Respiration 2006; 73:243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reichmuth KJ, Austin D, Skatrud JB, Young T. Association of sleep apnea and type II diabetes: a population-based study. Am J Respir Crit Care Med 2005; 172:1590.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bakker JP, Weng J, Wang R, et al. Associations between Obstructive Sleep Apnea, Sleep Duration, and Abnormal Fasting Glucose. The Multi-Ethnic Study of Atherosclerosis. Am J Respir Crit Care Med 2015; 192:745.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Einvik G, Røsjø H, Randby A, et al. Severity of obstructive sleep apnea is associated with cardiac troponin I concentrations in a community-based sample: data from the Akershus Sleep Apnea Project. Sleep 2014; 37:1111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Young T, Finn L, Peppard PE, et al. Sleep disordered breathing and mortality: eighteen-year follow-up of the Wisconsin sleep cohort. Sleep 2008; 31:1071.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martínez-García MA, Campos-Rodríguez F, Catalán-Serra P, et al. Cardiovascular mortality in obstructive sleep apnea in the elderly: role of long-term continuous positive airway pressure treatment: a prospective observational study. Am J Respir Crit Care Med 2012; 186:909.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hla KM, Young T, Hagen EW, et al. Coronary heart disease incidence in sleep disordered breathing: the Wisconsin Sleep Cohort Study. Sleep 2015; 38:677.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Milleron O, Pillière R, Foucher A, et al. Benefits of obstructive sleep apnoea treatment in coronary artery disease: a long-term follow-up study. Eur Heart J 2004; 25:728.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chami HA, Resnick HE, Quan SF, Gottlieb DJ. Association of incident cardiovascular disease with progression of sleep-disordered breathing. Circulation 2011; 123:1280.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buchner NJ, Sanner BM, Borgel J, Rump LC. Continuous positive airway pressure treatment of mild to moderate obstructive sleep apnea reduces cardiovascular risk. Am J Respir Crit Care Med 2007; 176:1274.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doherty LS, Kiely JL, Swan V, McNicholas WT. Long-term effects of nasal continuous positive airway pressure therapy on cardiovascular outcomes in sleep apnea syndrome. Chest 2005; 127:2076.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin YK, Lai MS, Chen YC, et al. Hypoxia and reoxygenation modulate the arrhythmogenic activity of the pulmonary vein and atrium. Clin Sci (Lond) 2012; 122:121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mehra R, Benjamin EJ, Shahar E, et al. Association of nocturnal arrhythmias with sleep-disordered breathing: The Sleep Heart Health Study. Am J Respir Crit Care Med 2006; 173:910.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gami AS, Friedman PA, Chung MK, et al. Therapy Insight: interactions between atrial fibrillation and obstructive sleep apnea. Nat Clin Pract Cardiovasc Med 2005; 2:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tanigawa T, Yamagishi K, Sakurai S, et al. Arterial oxygen desaturation during sleep and atrial fibrillation. Heart 2006; 92:1854.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caples SM, Somers VK. Sleep-disordered breathing and atrial fibrillation. Prog Cardiovasc Dis 2009; 51:411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mehra R, Stone KL, Varosy PD, et al. Nocturnal Arrhythmias across a spectrum of obstructive and central sleep-disordered breathing in older men: outcomes of sleep disorders in older men (MrOS sleep) study. Arch Intern Med 2009; 169:1147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Monahan K, Storfer-Isser A, Mehra R, et al. Triggering of nocturnal arrhythmias by sleep-disordered breathing events. J Am Coll Cardiol 2009; 54:1797.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gami AS, Pressman G, Caples SM, et al. Association of atrial fibrillation and obstructive sleep apnea. Circulation 2004; 110:364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gami AS, Hodge DO, Herges RM, et al. Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation. J Am Coll Cardiol 2007; 49:565.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ng CY, Liu T, Shehata M, et al. Meta-analysis of obstructive sleep apnea as predictor of atrial fibrillation recurrence after catheter ablation. Am J Cardiol 2011; 108:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li L, Wang ZW, Li J, et al. Efficacy of catheter ablation of atrial fibrillation in patients with obstructive sleep apnoea with and without continuous positive airway pressure treatment: a meta-analysis of observational studies. Europace 2014; 16:1309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Qureshi WT, Nasir UB, Alqalyoobi S, et al. Meta-Analysis of Continuous Positive Airway Pressure as a Therapy of Atrial Fibrillation in Obstructive Sleep Apnea. Am J Cardiol 2015; 116:1767.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shukla A, Aizer A, Holmes D, et al. Effect of Obstructive Sleep Apnea Treatment on Atrial Fibrillation Recurrence: A Meta-Analysis. JACC Clin Electrophysiol 2015; 1:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yeghiazarians Y, Jneid H, Tietjens JR, et al. Obstructive Sleep Apnea and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation 2021; 144:e56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caples SM, Mansukhani MP, Friedman PA, Somers VK. The impact of continuous positive airway pressure treatment on the recurrence of atrial fibrillation post cardioversion: A randomized controlled trial. Int J Cardiol 2019; 278:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Traaen GM, Aakerøy L, Hunt TE, et al. Effect of Continuous Positive Airway Pressure on Arrhythmia in Atrial Fibrillation and Sleep Apnea: A Randomized Controlled Trial. Am J Respir Crit Care Med 2021; 204:573.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mehra R, Xu F, Babineau DC, et al. Sleep-disordered breathing and prothrombotic biomarkers: cross-sectional results of the Cleveland Family Study. Am J Respir Crit Care Med 2010; 182:826.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rossi VA, Stradling JR, Kohler M. Effects of obstructive sleep apnoea on heart rhythm. Eur Respir J 2013; 41:1439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alonso-Fernández A, García-Río F, Racionero MA, et al. Cardiac rhythm disturbances and ST-segment depression episodes in patients with obstructive sleep apnea-hypopnea syndrome and its mechanisms. Chest 2005; 127:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grimm W, Hoffmann J, Menz V, et al. Electrophysiologic evaluation of sinus node function and atrioventricular conduction in patients with prolonged ventricular asystole during obstructive sleep apnea. Am J Cardiol 1996; 77:1310.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raghuram A, Clay R, Kumbam A, et al. A systematic review of the association between obstructive sleep apnea and ventricular arrhythmias. J Clin Sleep Med 2014; 10:1155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gami AS, Olson EJ, Shen WK, et al. Obstructive sleep apnea and the risk of sudden cardiac death: a longitudinal study of 10,701 adults. J Am Coll Cardiol 2013; 62:610.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shamsuzzaman AS, Somers VK, Knilans TK, et al. Obstructive Sleep Apnea in Patients with Congenital Long QT Syndrome: Implications for Increased Risk of Sudden Cardiac Death. Sleep 2015; 38:1113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simantirakis EN, Schiza SI, Marketou ME, et al. Severe bradyarrhythmias in patients with sleep apnoea: the effect of continuous positive airway pressure treatment: a long-term evaluation using an insertable loop recorder. Eur Heart J 2004; 25:1070.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Becker H, Brandenburg U, Conradt R, et al. [Influence of nCPAP therapy on bradycardic arrhythmias in sleep apnea]. Pneumologie 1993; 47 Suppl 4:706.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ryan CM, Usui K, Floras JS, Bradley TD. Effect of continuous positive airway pressure on ventricular ectopy in heart failure patients with obstructive sleep apnoea. Thorax 2005; 60:781.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gami AS, Howard DE, Olson EJ, Somers VK. Day-night pattern of sudden death in obstructive sleep apnea. N Engl J Med 2005; 352:1206.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bradley TD, Floras JS. Sleep apnea and heart failure: Part II: central sleep apnea. Circulation 2003; 107:1822.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           White LH, Bradley TD. Role of nocturnal rostral fluid shift in the pathogenesis of obstructive and central sleep apnoea. J Physiol 2013; 591:1179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bradley TD, Logan AG, Kimoff RJ, et al. Continuous positive airway pressure for central sleep apnea and heart failure. N Engl J Med 2005; 353:2025.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arzt M, Floras JS, Logan AG, et al. Suppression of central sleep apnea by continuous positive airway pressure and transplant-free survival in heart failure: a post hoc analysis of the Canadian Continuous Positive Airway Pressure for Patients with Central Sleep Apnea and Heart Failure Trial (CANPAP). Circulation 2007; 115:3173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cowie MR, Woehrle H, Wegscheider K, et al. Adaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure. N Engl J Med 2015; 373:1095.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aurora RN, Bista SR, Casey KR, et al. Updated Adaptive Servo-Ventilation Recommendations for the 2012 AASM Guideline: "The Treatment of Central Sleep Apnea Syndromes in Adults: Practice Parameters with an Evidence-Based Literature Review and Meta-Analyses". J Clin Sleep Med 2016; 12:757.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uchôa CHG, Pedrosa RP, Javaheri S, et al. OSA and Prognosis After Acute Cardiogenic Pulmonary Edema: The OSA-CARE Study. Chest 2017; 152:1230.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holt A, Bjerre J, Zareini B, et al. Sleep Apnea, the Risk of Developing Heart Failure, and Potential Benefits of Continuous Positive Airway Pressure (CPAP) Therapy. J Am Heart Assoc 2018; 7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Javaheri S, Blackwell T, Ancoli-Israel S, et al. Sleep-disordered Breathing and Incident Heart Failure in Older Men. Am J Respir Crit Care Med 2016; 193:561.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chaouat A, Weitzenblum E, Krieger J, et al. Pulmonary hemodynamics in the obstructive sleep apnea syndrome. Results in 220 consecutive patients. Chest 1996; 109:380.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamakawa H, Shiomi T, Sasanabe R, et al. Pulmonary hypertension in patients with severe obstructive sleep apnea. Psychiatry Clin Neurosci 2002; 56:311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Minai OA, Ricaurte B, Kaw R, et al. Frequency and impact of pulmonary hypertension in patients with obstructive sleep apnea syndrome. Am J Cardiol 2009; 104:1300.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leuchte HH, Baumgartner RA, Nounou ME, et al. Brain natriuretic peptide is a prognostic parameter in chronic lung disease. Am J Respir Crit Care Med 2006; 173:744.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verma G, Marras T, Chowdhury N, Singer L. Health-related quality of life and 6 min walk distance in patients with idiopathic pulmonary fibrosis. Can Respir J 2011; 18:283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nagaoka M, Goda A, Takeuchi K, et al. Nocturnal Hypoxemia, But Not Sleep Apnea, Is Associated With a Poor Prognosis in Patients With Pulmonary Arterial Hypertension. Circ J 2018; 82:3076.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sajkov D, Wang T, Saunders NA, et al. Continuous positive airway pressure treatment improves pulmonary hemodynamics in patients with obstructive sleep apnea. Am J Respir Crit Care Med 2002; 165:152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arias MA, García-Río F, Alonso-Fernández A, et al. Pulmonary hypertension in obstructive sleep apnoea: effects of continuous positive airway pressure: a randomized, controlled cross-over study. Eur Heart J 2006; 27:1106.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lippi G, Mattiuzzi C, Franchini M. Sleep apnea and venous thromboembolism. A systematic review. Thromb Haemost 2015; 114:958.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7705 Version 53.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26316620" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Sex-Specific Association of Sleep Apnea Severity With Subclinical Myocardial Injury, Ventricular Hypertrophy, and Heart Failure Risk in a Community-Dwelling Cohort: The Atherosclerosis Risk in Communities-Sleep Heart Health Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19101028" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Obstructive sleep apnoea and its cardiovascular consequences.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19265785" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : The price of obstructive sleep apnea-hypopnea: hypertension and other ill effects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23331757" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Association between obstructive sleep apnea severity and endothelial dysfunction in an increased background of cardiovascular burden.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10805822" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Prospective study of the association between sleep-disordered breathing and hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19688045" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Sleep-disordered breathing and mortality: a prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20625114" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25927872" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Severity of OSA is an independent predictor of incident atrial fibrillation hospitalization in a large sleep-clinic cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20339144" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Obstructive sleep apnea-hypopnea and incident stroke: the sleep heart health study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15781100" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22618923" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Effect of continuous positive airway pressure on the incidence of hypertension and cardiovascular events in nonsleepy patients with obstructive sleep apnea: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26914592" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Effect of Positive Airway Pressure on Cardiovascular Outcomes in Coronary Artery Disease Patients with Nonsleepy Obstructive Sleep Apnea. The RICCADSA Randomized Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20847081" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Early treatment of obstructive apnoea and stroke outcome: a randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27571048" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : CPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28697252" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Association of Positive Airway Pressure With Cardiovascular Events and Death in Adults With Sleep Apnea: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30529774" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Continuous positive airway pressure for adults with obstructive sleep apnea and cardiovascular disease: a meta-analysis of randomized trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11936531" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Obstructive sleep apnoea and urine catecholamines in hypertensive males: a population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10587337" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Nocturnal continuous positive airway pressure decreases daytime sympathetic traffic in obstructive sleep apnea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24351803" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Obstructive sleep apnea and diurnal nondipping hemodynamic indices in patients at increased cardiovascular risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10678860" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Obstructive sleep apnoea syndrome as a risk factor for hypertension: population study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10770144" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9250236" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Population-based study of sleep-disordered breathing as a risk factor for hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10588600" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Sleep-related breathing disorder is an independent risk factor for systemic hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10927725" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Association of hypertension and sleep-disordered breathing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22523363" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : At 68 years, unrecognised sleep apnoea is associated with elevated ambulatory blood pressure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22508535" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Dysfunctional sleep in persons with spinal cord injuries and disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23471270" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Endothelial dysfunction and arterial stiffness in ischemic stroke: the role of sleep-disordered breathing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22618924" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Association between treated and untreated obstructive sleep apnea and risk of hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19264976" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Prospective study of sleep-disordered breathing and hypertension: the Sleep Heart Health Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21868499" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Obstructive sleep apnea and systemic hypertension: longitudinal study in the general population: the Vitoria Sleep Cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15699282" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Age-dependent associations between sleep-disordered breathing and hypertension: importance of discriminating between systolic/diastolic hypertension and isolated systolic hypertension in the Sleep Heart Health Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25295854" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Obstructive sleep apnea during REM sleep and hypertension. results of the Wisconsin Sleep Cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18079220" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Obstructive sleep apnea and resistant hypertension: a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25126027" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Association of severe obstructive sleep apnea and elevated blood pressure despite antihypertensive medication use.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11812555" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Ambulatory blood pressure after therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised parallel trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11179104" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Randomized placebo-controlled trial of continuous positive airway pressure on blood pressure in the sleep apnea-hypopnea syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12515745" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10642289" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Effect of continuous positive airway pressure on blood pressure : a placebo trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17452537" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : The impact of continuous positive airway pressure on blood pressure in patients with obstructive sleep apnea syndrome: evidence from a meta-analysis of placebo-controlled randomized trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17548722" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Effect of nocturnal nasal continuous positive airway pressure on blood pressure in obstructive sleep apnea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22168642" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : CPAP for the metabolic syndrome in patients with obstructive sleep apnea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17393240" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Impact of continuous positive airway pressure therapy on blood pressure in patients with obstructive sleep apnea hypopnea: a meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23066375" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : The effect of continuous positive airway pressure treatment on blood pressure: a systematic review and meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24918372" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : CPAP versus oxygen in obstructive sleep apnea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26039959" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Blood Pressure Increases in OSA due to Maintained Neurovascular Sympathetic Transduction: Impact of CPAP.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26624827" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : CPAP vs Mandibular Advancement Devices and Blood Pressure in Patients With Obstructive Sleep Apnea: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24077181" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Effect of CPAP on blood pressure in patients with OSA/hypopnea a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14615107" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24327037" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Effect of CPAP on blood pressure in patients with obstructive sleep apnea and resistant hypertension: the HIPARCO randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24733980" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Blood pressure improvement with continuous positive airway pressure is independent of obstructive sleep apnea severity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20522795" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Comparison of continuous positive airway pressure and valsartan in hypertensive patients with sleep apnea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16778262" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Effect of continuous positive airway pressure on ambulatory BP in patients with sleep apnea and hypertension: a placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16455835" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Continuous positive airway pressure does not reduce blood pressure in nonsleepy hypertensive OSA patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14597482" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Controlled trial of continuous positive airway pressure in obstructive sleep apnea and heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11388814" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Treatment with continuous positive airway pressure is not effective in patients with sleep apnea but no daytime sleepiness. a randomized, controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25601933" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Effects of continuous positive airway pressure treatment on clinic and ambulatory blood pressures in patients with obstructive sleep apnea and resistant hypertension: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20335381" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Control of hypertension in nonsleepy patients with obstructive sleep apnea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23111478" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Continuous positive airway pressure improves sleepiness but not calculated vascular risk in patients with minimally symptomatic obstructive sleep apnoea: the MOSAIC randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20007932" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Long-term effect of continuous positive airway pressure in hypertensive patients with sleep apnea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25125635" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Long-term effects of continuous positive airway pressure on blood pressure and prognosis in hypertensive patients with coronary heart disease and obstructive sleep apnea: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27452767" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Effect of CPAP Withdrawal on BP in OSA: Data from Three Randomized Controlled Trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24918371" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : CPAP, weight loss, or both for obstructive sleep apnea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23372472" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Effect of oral appliances on blood pressure in obstructive sleep apnea: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22821223" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Effects of treatment with oral appliance on 24-h blood pressure in patients with obstructive sleep apnea and hypertension: a randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16387944" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Obstructive sleep apnoea and its therapy influence high-density lipoprotein cholesterol serum levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16478836" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Serum cardiovascular risk factors in obstructive sleep apnea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16549947" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Sleep apnoea-hypopnoea index is an independent predictor of high-sensitivity C-reactive protein elevation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16192452" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Association of sleep apnea and type II diabetes: a population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26084035" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Associations between Obstructive Sleep Apnea, Sleep Duration, and Abnormal Fasting Glucose. The Multi-Ethnic Study of Atherosclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24882906" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Severity of obstructive sleep apnea is associated with cardiac troponin I concentrations in a community-based sample: data from the Akershus Sleep Apnea Project.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18714778" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Sleep disordered breathing and mortality: eighteen-year follow-up of the Wisconsin sleep cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22983957" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Cardiovascular mortality in obstructive sleep apnea in the elderly: role of long-term continuous positive airway pressure treatment: a prospective observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25515104" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Coronary heart disease incidence in sleep disordered breathing: the Wisconsin Sleep Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15120882" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Benefits of obstructive sleep apnoea treatment in coronary artery disease: a long-term follow-up study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21403097" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Association of incident cardiovascular disease with progression of sleep-disordered breathing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17673692" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Continuous positive airway pressure treatment of mild to moderate obstructive sleep apnea reduces cardiovascular risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15947323" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Long-term effects of nasal continuous positive airway pressure therapy on cardiovascular outcomes in sleep apnea syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21880017" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Hypoxia and reoxygenation modulate the arrhythmogenic activity of the pulmonary vein and atrium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16424443" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Association of nocturnal arrhythmias with sleep-disordered breathing: The Sleep Heart Health Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16265458" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Therapy Insight: interactions between atrial fibrillation and obstructive sleep apnea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17105888" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Arterial oxygen desaturation during sleep and atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19249447" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Sleep-disordered breathing and atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19546416" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Nocturnal Arrhythmias across a spectrum of obstructive and central sleep-disordered breathing in older men: outcomes of sleep disorders in older men (MrOS sleep) study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19874994" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Triggering of nocturnal arrhythmias by sleep-disordered breathing events.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15249509" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Association of atrial fibrillation and obstructive sleep apnea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17276180" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21529734" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Meta-analysis of obstructive sleep apnea as predictor of atrial fibrillation recurrence after catheter ablation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24696222" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Efficacy of catheter ablation of atrial fibrillation in patients with obstructive sleep apnoea with and without continuous positive airway pressure treatment: a meta-analysis of observational studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26482182" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Meta-Analysis of Continuous Positive Airway Pressure as a Therapy of Atrial Fibrillation in Obstructive Sleep Apnea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29759338" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Effect of Obstructive Sleep Apnea Treatment on Atrial Fibrillation Recurrence: A Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34148375" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Obstructive Sleep Apnea and Cardiovascular Disease: A Scientific Statement From the American Heart Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30522886" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : The impact of continuous positive airway pressure treatment on the recurrence of atrial fibrillation post cardioversion: A randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33938787" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Effect of Continuous Positive Airway Pressure on Arrhythmia in Atrial Fibrillation and Sleep Apnea: A Randomized Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20508215" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Sleep-disordered breathing and prothrombotic biomarkers: cross-sectional results of the Cleveland Family Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23258782" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Effects of obstructive sleep apnoea on heart rhythm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15653957" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Cardiac rhythm disturbances and ST-segment depression episodes in patients with obstructive sleep apnea-hypopnea syndrome and its mechanisms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8677871" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Electrophysiologic evaluation of sinus node function and atrioventricular conduction in patients with prolonged ventricular asystole during obstructive sleep apnea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25317099" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : A systematic review of the association between obstructive sleep apnea and ventricular arrhythmias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23770166" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Obstructive sleep apnea and the risk of sudden cardiac death: a longitudinal study of 10,701 adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26118557" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Obstructive Sleep Apnea in Patients with Congenital Long QT Syndrome: Implications for Increased Risk of Sudden Cardiac Death.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15191779" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Severe bradyarrhythmias in patients with sleep apnoea: the effect of continuous positive airway pressure treatment: a long-term evaluation using an insertable loop recorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8153092" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : [Influence of nCPAP therapy on bradycardic arrhythmias in sleep apnea].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15994252" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Effect of continuous positive airway pressure on ventricular ectopy in heart failure patients with obstructive sleep apnoea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15788497" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Day-night pattern of sudden death in obstructive sleep apnea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12682029" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Sleep apnea and heart failure: Part II: central sleep apnea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23230237" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Role of nocturnal rostral fluid shift in the pathogenesis of obstructive and central sleep apnoea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16282177" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Continuous positive airway pressure for central sleep apnea and heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17562959" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Suppression of central sleep apnea by continuous positive airway pressure and transplant-free survival in heart failure: a post hoc analysis of the Canadian Continuous Positive Airway Pressure for Patients with Central Sleep Apnea and Heart Failure Trial (CANPAP).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26323938" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Adaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27092695" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Updated Adaptive Servo-Ventilation Recommendations for the 2012 AASM Guideline: "The Treatment of Central Sleep Apnea Syndromes in Adults: Practice Parameters with an Evidence-Based Literature Review and Meta-Analyses".
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28823814" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : OSA and Prognosis After Acute Cardiogenic Pulmonary Edema: The OSA-CARE Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29934418" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Sleep Apnea, the Risk of Developing Heart Failure, and Potential Benefits of Continuous Positive Airway Pressure (CPAP) Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26502092" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Sleep-disordered Breathing and Incident Heart Failure in Older Men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8620709" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Pulmonary hemodynamics in the obstructive sleep apnea syndrome. Results in 220 consecutive patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12047610" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Pulmonary hypertension in patients with severe obstructive sleep apnea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19840581" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Frequency and impact of pulmonary hypertension in patients with obstructive sleep apnea syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16415273" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Brain natriuretic peptide is a prognostic parameter in chronic lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21969931" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Health-related quality of life and 6 min walk distance in patients with idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30333436" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Nocturnal Hypoxemia, But Not Sleep Apnea, Is Associated With a Poor Prognosis in Patients With Pulmonary Arterial Hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11790646" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Continuous positive airway pressure treatment improves pulmonary hemodynamics in patients with obstructive sleep apnea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16497687" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Pulmonary hypertension in obstructive sleep apnoea: effects of continuous positive airway pressure: a randomized, controlled cross-over study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25994924" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Sleep apnea and venous thromboembolism. A systematic review.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
